<DOC>
	<DOCNO>NCT00268684</DOCNO>
	<brief_summary>The objective study determine either temozolomide erlotinib combine WBRT SRS improve survival compare WBRT SRS alone.Ptients histologically confirm NSCLC presence 1-3 intraparenchymal brain metastasis randomize 3 arm . All patient receive WBRT SRS . The patient arm 1 receive radiation treatment , arm 2 patient treat temozolomide arm 3 patient receive erlotinib</brief_summary>
	<brief_title>Comparison Study WBRT SRS Alone Versus With Temozolomide Erlotinib Patients With Brain Metastases NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Histologically confirm nonsmall cell lung cancer presence 13 intraparenchymal brain metastasis . 2 . A contrastenhanced MRI demonstrate presence 13 brain metastasis perform within two week prior registration . 3 . The contrastenhancing intraparenchymal brain tumor must well circumscribe must maximum diameter ≤ 4.0 cm direction enhance scan . If multiple lesion present one lesion maximum diameter , ( ) must exceed 3.0 cm maximum diameter . 4 . Patients present symptom brain metastasis time initial diagnosis eligible need demonstrate one month stable scan . 5 . Age 18 year old . 6 . Zubrod 01 7 . Neurologic Function Status 0 , 1 , 2 . 8 . Patients may stable extracranial metastasis . 9 . Contrastenhancing CT scan chest , abdomen pelvis , bone scan determine extent extracranial malignant disease . 10 . Adequate bone marrow reserve 11 . Patients randomize receive erlotinib enzyme induce seizure medicine include phenytoin , carbamazepine , rifampicin , barbiturates must convert nonenzyme inducing antiseizure medication . Patients Arm 3 able start treatment immediately convert . 12 . Patient must sign studyspecific inform consent form . If patient ’ mental status preclude his/her give inform consent , write informed consent may give patient ’ legal representative . 1 . Major medical illness psychiatric impairment 2 . Patients undergone complete resection know brain metastases.Patients undergone subtotal resection eligible provide residual disease =/ &lt; 4.0 cm maximum diameter . 3 . Inability obtain histologic proof NSCLC . 4 . Patients leptomeningeal metastasis document MRI CSF evaluation . 5 . Clinical radiographic evidence progression ( study lesion ( ) ) within one month prior enrollment . ( Patients brain metastasis initial presentation eligible need demonstrate one month stable scan ) . 6 . Patients metastasis within 10 mm optic apparatus portion optic nerve chiasm would include high dose SRS boost field . 7 . Patients metastases brainstem , midbrain , pons , medulla . 8 . Patients liver metastasis . 9 . Previous cranial radiation . 10 . Women pregnant nursing 11 . Patients HIV positive eligible . 12 . Any evidence clinically active interstitial lung disease 13 . Treatment nonapproved investigational drug within 30 day Day 1 studytreatment . 14 . Concomitant use St. John ’ Wort . 15 . History allergic reaction attribute compound similar chemical biologic composition erlotinib temozolomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
</DOC>